Physician profile
Raymond Candelaria
NPI 1023775848
$9,876.37
in general payments reported to CMS, 2019-2025
36 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $996 · 2023: $3,330 · 2024: $2,664 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,880.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,375.88 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,270.96 | 2022-2025 | |
| Lilly USA, LLC | $1,028.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $806.19 | 2022-2025 | |
| Pfizer INC. | $778.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $719.22 | 2022-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $505.71 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.57 | 2022-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $370.99 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $326.39 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $247.00 | 2023-2025 | Auvelity |
| Amgen INC. | $204.92 | 2022-2025 | Evenity, Prolia, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.87 | 2022-2025 | Caplyta |
| Corium, LLC | $188.75 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $183.02 | 2023-2025 | Ingrezza, Ongentys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $179.14 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Alkermes, INC. | $167.20 | 2022-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $159.86 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $97.96 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $94.88 | 2023-2025 | Trintellix |
| Ironwood Pharmaceuticals, INC | $92.36 | 2023-2024 | Linzess |
| Esperion Therapeutics, INC. | $66.18 | 2022-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $63.23 | 2023-2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $54.24 | 2023 | Jornay Pm |
| Antares Pharma, INC. | $45.15 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $38.20 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $29.71 | 2024 | Korlym |
| Tris Pharma INC | $29.06 | 2023-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $24.64 | 2023 | |
| Daiichi Sankyo INC. | $23.04 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $22.47 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $20.56 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2025 | Austedo Xr |
| Cranial Technologies, INC | $16.56 | 2023 | Doc Band |
| Astellas Pharma US INC | $13.83 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $12.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Candelaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.